Effect of recombinant hirudin (LU 52369) on reocclusion rates after thrombolysis in rabbits.
The effect of recombinant hirudin (r-hirudin, LU 52369) and unfractionated heparin on recombinant tissue-type plasminogen activator (rt-PA; LU 50232) thrombolysis and reocclusion rates after successful thrombolysis was studied in a copper-coil-induced thrombus model in the iliac artery of anesthetized rabbits. Simultaneous administration of rt-PA and recombinant hirudin (r-hirudin) at a dose not affecting the partial thromboplastin time (PTT) increased the number of recanalized arteries significantly. The incidence of reocclusion was drastically reduced from 100% to less than 25%. At a dose increasing PTT twofold, unfractionated heparin had no effect on the incidence of reperfusion and reocclusion. These experimental data indicate that the combination of rt-PA with low-dose r-hirudin may be useful for the prevention of early reocclusion in thrombolytic therapy.
Rübsamen
K
K
Knoll AG, Department of Angiology, Ludwigshafen, FRG.
Eschenfelder
V
V
D000818:Animals; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005340:Fibrinogen / Q000032:analysis; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D024764:Hirudin Therapy; D007083:Iliac Artery / Q000293:injuries; D011817:Rabbits; D011994:Recombinant Proteins / Q000627:therapeutic use; D012008:Recurrence; D013917:Thrombin / Q000037:antagonists & inhibitors; D015912:Thrombolytic Therapy; D013927:Thrombosis / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D000979:alpha-2-Antiplasmin / Q000032:analysis
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D000979:alpha-2-Antiplasmin; D005340:Fibrinogen; D013917:Thrombin